Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Andecaliximab in Fibrodysplasia Ossificans Progressiva
NCT06508021Phase 3Active, not recruiting
- Sponsor
- āshibio
- Start
- Oct 2024
- Primary completion
- Feb 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of andecaliximab in fibrodysplasia ossificans progressiva (FOP) (5 arms), sponsored by āshibio. Primary endpoint: Number of New Heterotopic Ossification Lesions at 53 weeks. Started Oct 2024; status: active, not recruiting.
02
Drugs
andecaliximab
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on NCT06508021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06508021.